Home
Storia in 1 fonti
Angitia ends Phase 3 in disc disease; Abivax raises $800M on colitis data
Angitia halts a Phase 3 disc-disease trial, Abivax prices an upsized $800M offering, and AlzeCure lands a $2.2B NeuroRestore deal with QuantumCell.
Raccontata da
endpoints.news
Timeline cronologica
- ·
Angitia ends Phase 3 in disc disease; Abivax raises $800M on colitis data
Angitia halts a Phase 3 disc-disease trial, Abivax prices an upsized $800M offering, and AlzeCure lands a $2.2B NeuroRestore deal with QuantumCell.
- ·
Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup
Vertex's Casgevy wins pediatric approval, United Therapeutics buys Thymmune for up to $300M, plus deals from Insilico, Fosun and Abbisko.